Neurobots

Neurobots operates across neurotechnology, rehabilitation, medical devices, and digital health from Recife, Brazil. Its portfolio spans both clinical devices and software-oriented services: Myobots captures muscle activity through surface electromyography, Exobots targets motor rehabilitation through a brain-machine interface, and Neurobots Lab offers custom hardware and software development. The company also describes pelvic physiotherapy biofeedback, neurofeedback, training, and smart-clinic products, suggesting a broader scope than a single-device business. The clearest differentiator in the available company information is this combination of neuroengineering products and custom development, alongside an stated focus on making healthcare technology accessible. The company’s market position is therefore best described by its product mix and regional base, rather than by unsupported claims about market share, commercial leadership, or relative performance.

Neurobots was founded in 2016 and has a recorded Seed round dated Jan 1, 2019, with Eretz.bio identified as its investor. The round’s amount is unavailable, and there is no later financing event in the available company information. Its product set indicates development across several areas: Myobots for muscle-signal monitoring, Exobots for motor recovery, Batom Inteligente (Smart Lipstick) as an assistive device, and Neurobots Lab for custom projects. The website also describes pelvic physiotherapy biofeedback, neurofeedback, practical training, and smart-clinic tools. The company reports more than 500 clients, 10,000 sessions, and 1,300 patients without dates or supporting time series. Those figures signal claimed usage, but do not reveal growth velocity. The 2019 Seed round is the clearest dated inflection point; subsequent trajectory remains uncertain.